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One Step Closer to an Ebola Virus Vaccine
Daniel G. Bausch, M.D., M.P.H.&T.M.
Despite the slowing and eventual halting of the 
spread of Ebola virus disease (EVD) in West Af­
rica,1,2 the battle for preventing and managing 
future outbreaks is still on. This is no time to be 
complacent. The scale of the outbreak, in which 
every few days during the early part of the out­
break about the same number of cases accrued 
as occurred during the entire 3­month outbreak 
in Gulu, Uganda, in 2000–2001 — previously the 
largest outbreak on record — prompted us to 
pull out all the stops, albeit after a slow start.3 
Vaccines are a key weapon in our armamentarium 
against EVD. For some years, a number of prom­
ising vaccine candidates have been identified, 
with many more in development. The two lead­
ing candidates are vectored vaccines in which 
the Ebola virus glycoprotein is presented in a 
replication­incompetent chimpanzee adenovirus 3 
(cAd3) or a replication­competent vesicular sto­
matitis virus (VSV). Both vaccines showed 100% 
protection in nonhuman primates at 4 to 5 weeks 
after single doses were administered and were 
rushed into phase 1 trials in hopes that the 
promise of a vaccine that could help stem an 
epidemic of EVD could be more than theoretical.
Ledgerwood and colleagues now present in 
the Journal the final results of the phase 1 VRC 
207 trial, a nonrandomized, open­label trial of 
two dose levels of a cAd3­vectored bivalent vac­
cine against the two most virulent species of 
ebolavirus, Zaire and Sudan.4 They conclude that 
the vaccine is without significant safety concerns 
and is immunogenic, inducing strong humoral 
and cell­mediated responses. Although the re­
sults of the trial are indeed promising, questions 
remain; both immunogenicity and reactogenicity 
were dose­dependent. The higher dose, which 
was required to generate the more vigorous im­
mune response, was also associated with sys­
temic symptoms in 70% of the participants, in­
cluding one in whom a high fever (temperature, 
39.9°C) developed, and with transient leukopenia 
in 20%. There were no major adverse effects, but 
the sample size (10 persons at each dose level) is 
too small to draw firm conclusions in this re­
gard. Of particular concern is that the virus­
specific CD8 T­cell response, which may be a key 
correlate of protection,5 was only 20% in the 
lower­dose group and 70% in the higher­dose 
group. Getting the dose right has relevance not 
only for ensuring individual protection and mini­
mizing adverse effects, but also for stretching 
the vaccine supply to the maximum number of 
doses possible to combat the ongoing outbreak.
Interpretation of the findings of the study by 
Ledgerwood et al., as with all studies of filovirus 
vaccines, is hampered by a lack of knowledge 
regarding the specific correlates of immunity, 
although, as the authors point out, the immune 
responses observed in their study involving hu­
mans are consistent with those associated with 
protection in efficacy studies in nonhuman pri­
mates.5 The matter is further complicated by a 
lack of standardization of stock viruses6 and the 
fact that, to achieve 100% mortality in control 
animals — and thus interpretable results — in 
studies in nonhuman primates, an extremely high 
challenge dose of virus (1000 plaque­forming 
units) is used, which is probably orders of mag­
nitude higher than the inoculum that typically 
infects a human. Until the correlates of immu­
nity are better understood, it is impossible to say 
whether the immune response shown at the 
lower dose in the study by Ledgerwood et al., 
which caused fewer side effects, is “good enough.” 
Will similar results be observed in West Africa, 
where malaria is holoendemic and has been as­
sociated with diminished immunogenicity with 
other vectored vaccines?7 At exactly what time 
point after vaccination is adequate immunity 
conferred? This is an important question, given 
the urgency of this type of situation. Will it be 
necessary to administer a booster with a modi­
fied vaccinia Ankara (MVA) vaccine expressing 
the Ebola glycoprotein, which has been shown 
to increase the duration of immunity but would 
considerably complicate delivery?8 Results from 
ongoing phase 1 trials of a monovalent cAd3­
EBO Zaire vaccine, which may be more immuno­
genic than a bivalent formation,9 as well as of 
the VSV­vectored vaccine, in various locations in 
the United States, Europe, and Africa (outside 
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the epidemic area for EVD), are informing the 
answers to these important questions.
Perhaps one of the only silver linings of the 
EVD crisis that shook West Africa several years 
ago is that the event pushed therapeutics and 
vaccines for EVD, which had previously been rela­
tively stalled in development despite the promis­
ing results in nonhuman primates, into acceler­
ated production and clinical trials. Assuming 
that the findings of Ledgerwood et al. are con­
firmed, especially in African populations, cAd3­
EBO certainly warrants efficacy trials, but there 
are difficult decisions regarding the best dose 
and the trial design. In the current report, the 
authors have updated their findings, presenting 
evidence of continued immune humoral and 
CD4 and CD8 cellular immune responses at 48 
weeks after vaccination, although the peak re­
sponse was still at week 4. Whether the immune 
response at 48 weeks is still sufficient to confer 
protection is unknown, given the previously men­
tioned lack of specific correlates of immunity. 
The authors note subsequently published results 
of phase 1 and 2 studies of a monovalent cAd3­
EBO vaccine, sometimes followed by an MVA 
boost, in which 1×1011 particle units was deter­
mined to be the best dose on the basis of the 
immunogenicity and adverse event profile. Al­
though use of the monovalent cAd3­EBO vaccine 
alone many be sufficient to confer short­term 
immunity, which is of clear value for outbreak 
control, the use of adjuvants may be needed for 
longer­term protection. Phase 3 trials are planned, 
but important questions remain: can traditional 
phase 2 and 3 efficacy trials be performed in 
West Africa, given the many ethical considera­
tions; should the cAd3 and VSV vaccines be 
compared head­to­head; what should the target 
population be; and can it all be arranged in a 
human trial, or will we ultimately need to turn 
to the Food and Drug Administration Animal 
Rule (which stipulates that under certain circum­
stances, the FDA may grant approval on the basis 
of well­controlled studies in animals)?10 The road 
is still long and there are many challenges, but we 
are nevertheless one step closer to a solution.
Disclosure forms provided by the author are available with the 
full text of this editorial at NEJM.org.
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A preliminary version of this editorial was published on Novem-
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